For the services rendered thereunder, the Company agreed to pay Cross Current $ 200 in cash and agreed to issue to the Advisor $ 500 of restricted shares of the Company’s common stock under the Compa…
the Company will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from the Company, up to $ 30,000 of the Company’s shares of common stock
Kairos Pharma, Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
KAPA-DEBT-10490
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
KAPA-DEBT-10489
Warrants outstanding: 4.29
90%
xbrl warrant detail from xbrl 2024-12-31.
Kairos Pharma, Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Kairos Pharma, Ltd..
Kairos Pharma, Ltd. Ownership
Holder
Name
Confidence
Evidence
KAPA-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 11 tracked holders.
Kairos Pharma, Ltd. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
